All Stories

  1. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs

    Article • Cardiovascular & Haematological Disorders - Drug Targets, January 2019, Bentham Science Publishers

    Dr Ota Fuchs

  2. Role of Immunomodulatory Drugs in the Treatment of Lymphoid and Myeloid Malignancies

    Article • April 2018, Bentham Science Publishers

    Dr Ota Fuchs

  3. Myelodysplastic Syndromes

    Article • September 2016, IntechOpen

    Dr Ota Fuchs

  4. Introductory Chapter: Myelodysplastic Syndromes

    Article • September 2016, IntechOpen

    Dr Ota Fuchs

  5. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide

    Article • European Journal Of Haematology, October 2014, Wiley

    Dr Ota Fuchs

  6. Markers for Diagnosis, Prognosis, and Therapy of Acute Myeloid Leukemia

    Article • December 2013, Taylor & Francis

    Dr Ota Fuchs

  7. Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia by Immunomodulatory and Epigenetic Drugs

    Article • May 2013, IntechOpen

    Dr Ota Fuchs

  8. P-106 Prognostic significance of NPM1, CEBPA, and MLL-PTDs mutations, EVI1, MN1 and ERG expressions in MDS and AML treated with azacitidine

    Article • Leukemia Research, May 2013, Elsevier

    Dr Ota Fuchs

  9. Targeting of NF-kappaB Signaling Pathway, other Signaling Pathways and Epigenetics in Therapy of Multiple Myeloma

    Article • Cardiovascular & Haematological Disorders - Drug Targets, March 2013, Bentham Science Publishers

    Dr Ota Fuchs

  10. Lenalidomide Therapy of Myelodysplastic Syndromes

    Article • Journal of Leukemia, January 2013, OMICS Publishing Group

    Dr Ota Fuchs

  11. Molecular Markers for Risk Stratification in Adult Acute Myeloid Leukemia with Normal Cytogenetics

    Article • December 2011, IntechOpen

    Dr Ota Fuchs

  12. Inhibition of TGF- Signaling for the Treatment of Tumor Metastasis and Fibrotic Diseases

    Article • Current Signal Transduction Therapy, January 2011, Bentham Science Publishers

    Dr Ota Fuchs

  13. Promising Activity of Mammalian Target of Rapamycin Inhibitors in Hematologic Malignancies Therapy

    Article • Current Signal Transduction Therapy, January 2011, Bentham Science Publishers

    Dr Ota Fuchs

  14. Transcription Factor NF-κB Inhibitors as Single Therapeutic Agents or in Combination with Classical Chemotherapeutic Agents for the Treatment of Hematologic Malignancies

    Article • Current Molecular Pharmacology, November 2010, Bentham Science Publishers

    Dr Ota Fuchs

  15. Transcription Factor NF-κB Inhibitors as Single Therapeutic Agents or in Combination with Classical Chemotherapeutic Agents for the Treatment of Hematologic Malignancies

    Article • Current Molecular Pharmacology, November 2010, Bentham Science Publishers

    Dr Ota Fuchs

  16. Transcription Factor NF-κB Inhibitors as Single Therapeutic Agents or in Combination with Classical Chemotherapeutic Agents for the Treatment of Hematologic Malignancies

    Article • Current Molecular Pharmacology, July 2010, Bentham Science Publishers

    Dr Ota Fuchs

  17. Nature of frequent deletions in CEBPA

    Article • Blood Cells Molecules and Diseases, November 2009, Elsevier

    Dr Ota Fuchs

  18. Antiproliferative and Proapoptotic Effects of Proteasome Inhibitors and their Combination with Histone Deacetylase Inhibitors on Leukemia Cells

    Article • Cardiovascular & Haematological Disorders - Drug Targets, March 2009, Bentham Science Publishers

    Dr Ota Fuchs

  19. Control of Iron Delivery to Haemoglobin in Erythroid Cells

    Article • May 2008, Wiley

    Dr Ota Fuchs

  20. CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma

    Article • Blood Cells Molecules and Diseases, May 2008, Elsevier

    Dr Ota Fuchs

  21. Ferrochelatase, glutathione peroxidase and transferrin receptor mRNA synthesis and levels in mouse erythroleukemia cells–mRNA synthesis and levels

    Article • Stem Cells, May 1993, Wiley

    Dr Ota Fuchs